Highly respected market analyst, Jim Cramer, holds a positive view on Thermo Fisher Scientific Inc. (TMO), predicting gradual improvement for the company with business expected to pick up around 2025-2026. A noteworthy development is a new accredited coverage from Scotiabank issuing a Sector Perform Recommendation.
Several significant strides have been made in the area of myeloid cancer clinical research and treatment through next-generation sequencing technology by the company. A quarterly dividend has been declared and Q3 2024 results reported. The organization also completed a gigantic $1B share buyback and signals strong future prospects with a staggering $3B authorization. China sales were flat YoY for the first three quarters 2024.
The Theromo Fisher stock is listed as one of the best low volatility stocks and one of the best stocks to invest in for the medium term by UBS. A $4B share buyback program has been launched with some insiders disposing of shares, indicating hesitancy. Despite a revenue dip, Thermo Fisher demonstrated resilient performance while also beating earnings estimates.
Furthermore, Thermo Fisher expanded its global footprint for drug product development and commercial manufacturing, strengthening its global market influence. However, bearish signals have been observed with insiders getting rid of stocks. Recent performance is also being questioned in relation to the company's attractive financial prospects.
Thermo Fisher Scientific TMO News Analytics from Wed, 24 Apr 2024 07:00:00 GMT to Sat, 28 Dec 2024 21:21:50 GMT - Rating 8 - Innovation 7 - Information 8 - Rumor 9
